Trial reportExperimental and clinical psychopharmacology2025
Exploratory study of heart rate variability among participants with opioid use disorder inducted on gabapentin versus placebo during outpatient buprenorphine-assisted transition to injection naltrexone.
Trial report in Experimental and clinical psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We assessed heart rate variability (HRV) as a measure of autonomic nervous system function during an ongoing double blind, placebo-controlled, trial of adjunct gabapentin during a buprenorphine-assisted taper and transition to injection naltrexone to explore how adjunctive pharmacotherapy and time influence autonomic nervous system activity and whether HRV metrics are predictive of treatment outcomes. Individuals with opioid use disorder who began their participation in an ongoing trial of adjunct gabapentin during an outpatient 10-day buprenorphine-assisted transition to injection naltrexone underwent experimental sessions at Weeks 1, 2, and 3 of the parent trial. HRV metrics were assessed for 2 min each while standing, sitting, and sitting while performing paced breathing (PB) using the ProComp2 System with sensor belt and analysis suite. Multiple imputation was used to analyze the HRV metrics due to some participants lacking data at all three weekly timepoints. Among 28 participants, logistic regression analyses indicated significant effects for frequency distributions and heart rate during PB exercises. Trends in frequency distribution during PB suggested potential influences of gabapentin on autonomic balance, resulting in lower HRV. Predictor variables for outcomes indicated a significant effect with higher low frequency/high frequency ratio during PB decreasing the odds of completing supervised withdrawal. Higher respiration rate and low frequency values while sitting showed trends and significant effects, respectively, for decreasing the odds of receiving Week 4 injection naltrexone. Selected HRV metrics change during supervised opioid withdrawal and are associated with treatment outcomes during supervised opioid withdrawal procedures. The significance of HRV metrics during PB exercises underscores the impact of specific activities on autonomic function, highlighting the importance of considering such effects when recording HRV metrics. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.